Are Smart Investors Making the Right Decision? Immunic Inc. (IMUX)

Immunic Inc. (NASDAQ: IMUX) stock jumped 3.91% on Friday to $1.86 against a previous-day closing price of $1.79. With 1.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.93 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.9150 whereas the lowest price it dropped to was $1.7000. The 52-week range on IMUX shows that it touched its highest point at $14.50 and its lowest point at $1.11 during that stretch. It currently has a 1-year price target of $21.17. Beta for the stock currently stands at 1.65.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMUX was up-trending over the past week, with a rise of 19.23%, but this was up by 64.60% over a month. Three-month performance dropped to -80.36% while six-month performance fell -52.91%. The stock lost -83.55% in the past year, while it has gained 32.86% so far this year. A look at the trailing 12-month EPS for IMUX yields -2.87 with Next year EPS estimates of -2.11. For the next quarter, that number is -0.74. This implies an EPS growth rate of -39.80% for this year and 27.50% for next year. EPS is expected to grow by 15.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 40.40%.

Float and Shares Shorts:

At present, 44.36 million IMUX shares are outstanding with a float of 36.07 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.66 million, which was 11.96% higher than short shares on Sep 14, 2022. In addition to Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A as the firm’s Exec. Chairman, Dr. Daniel Vitt serves as its CEO, Pres & Director.

Institutional Ownership:

Through their ownership of 81.95% of IMUX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 46.20% of IMUX, in contrast to 3.62% held by mutual funds. Shares owned by individuals account for 2.45%. As the largest shareholder in IMUX with 9.07% of the stake, Deep Track Capital LP holds 4,022,989 shares worth 4,022,989. A second-largest stockholder of IMUX, RTW Investments LP, holds 2,761,968 shares, controlling over 6.23% of the firm’s shares. Commodore Capital LP is the third largest shareholder in IMUX, holding 2,693,013 shares or 6.07% stake. With a 1.60% stake in IMUX, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 710,074 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.74% of IMUX stock, is the second-largest Mutual Fund holder. It holds 327,341 shares valued at 0.46 million. Fidelity Extended Market Index Fu holds 0.33% of the stake in IMUX, owning 144,176 shares worth 0.2 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMUX since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMUX analysts setting a high price target of $39.00 and a low target of $5.00, the average target price over the next 12 months is $16.50. Based on these targets, IMUX could surge 1996.77% to reach the target high and rise by 168.82% to reach the target low. Reaching the average price target will result in a growth of 787.1% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. IMUX will report FY 2022 earnings on 02/22/2024. Analysts have provided yearly estimates in a range of -$2.54 being high and -$3.69 being low. For IMUX, this leads to a yearly average estimate of -$2.95. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Immunic Inc. surprised analysts by -$0.02 when it reported -$0.69 EPS against a consensus estimate of -$0.67. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.44 and the low estimate is -$1.39. The average estimate for the next quarter is thus -$0.74.

Summary of Insider Activity:

Insiders traded IMUX stock several times over the past three months with 5 Buys and 0 Sells. In these transactions, 113,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 138,000 while 6,000 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *